These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8882962)

  • 21. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
    Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
    Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective study of VEC-POB and POCE chemotherapy in aggressive non-Hodgkin's lymphoma.
    Ezzat AA; Raja MA; Berry J; Abd El-Warith A; Khan BA; Rhydderch DC
    Am J Clin Oncol; 1997 Apr; 20(2):179-83. PubMed ID: 9124196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
    Gordon LI; Anderson J; Habermann TM; Winter JN; Glick J; Schilder RJ; Cassileth P
    J Clin Oncol; 1996 Apr; 14(4):1275-81. PubMed ID: 8648384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
    Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
    Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
    Zinzani PL; Storti S; Zaccaria A; Moretti L; Magagnoli M; Pavone E; Gentilini P; Guardigni L; Gobbi M; Fattori PP; Falini B; Lauta VM; Bendandi M; Gherlinzoni F; De Renzo A; Zaja F; Mazza P; Volpe E; Bocchia M; Aitini E; Tabanelli M; Leone G; Tura S
    Blood; 1999 Jul; 94(1):33-8. PubMed ID: 10381495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
    Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
    Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
    Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
    Zinzani PL; Pavone E; Storti S; Moretti L; Fattori PP; Guardigni L; Falini B; Gobbi M; Gentilini P; Lauta VM; Bendandi M; Gherlinzoni F; Magagnoli M; Venturi S; Aitini E; Tabanelli M; Leone G; Liso V; Tura S
    Blood; 1997 Jun; 89(11):3974-9. PubMed ID: 9166835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic strategies in intermediate grade lymphomas in elderly patients. The Italian Multiregional non Hodgkin's Lymphoma Study Group (IMRNHLSG).
    Bertini M
    Hematol Oncol; 1993; 11 Suppl 1():52-8. PubMed ID: 7683623
    [No Abstract]   [Full Text] [Related]  

  • 33. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
    Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
    J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
    Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
    Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
    J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
    Gómez H; Hidalgo M; Casanova L; Colomer R; Pen DL; Otero J; Rodríguez W; Carracedo C; Cortés-Funes H; Vallejos C
    J Clin Oncol; 1998 Jun; 16(6):2065-9. PubMed ID: 9626205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
    Coiffier B; Gisselbrecht C; Vose JM; Tilly H; Herbrecht R; Bosly A; Armitage JO
    J Clin Oncol; 1991 Feb; 9(2):211-9. PubMed ID: 1703226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consolidation therapy with idarubicin, cisplatin and prednisone (CIP) after P-VABEC regimen in the treatment of intermediate and high grade non-Hodgkin's lymphoma of the elderly.
    Caracciolo F; Capochiani E; Papineschi F; Petrini M
    Leuk Lymphoma; 1997 Jan; 24(3-4):355-61. PubMed ID: 9156666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.